Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay

Journal of Bacteriology

Volumn 197, Issue 10, 2015, Pages 1726-1734

  Nayar, Asha S ^a   Dougherty, Thomas J ^a,c   Ferguson, Keith E ^a   Granger, Brett A ^a   McWilliams, Lisa ^a   Stacey, Clare ^a   Leach, Lindsey J ^a   Narita, Shin ichiro ^b   Tokuda, Hajime ^b   Miller, Alita A ^a   Brown, Dean G ^a   McLeod, Sarah M ^a  

^a ASTRAZENECA   (United Kingdom)

^b MORIOKA UNIVERSITY   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LIPOPOLYSACCHARIDE; BETA LACTAMASE AMPC; LEVOFLOXACIN; LIPID A; LIPOPOLYSACCHARIDE; MEROPENEM; PIPERAZINE DERIVATIVE; PYRAZOLE; SULFONYL PIPERAZINE; TETRACYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ENZYME INHIBITOR; PYRAZOLE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOSYNTHESIS; CATALYST; CELL VIABILITY; CHEMICAL STRUCTURE; CHROMOSOME DELETION; CITROBACTER FREUNDII; CROSS RESISTANCE; DRUG MECHANISM; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; FRAMESHIFT MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; ANTIBIOTIC RESISTANCE; CELL WALL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; PROCEDURES; REPORTER GENE;

BACTERIA (MICROORGANISMS); CITROBACTER FREUNDII; ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; CELL WALL; CITROBACTER FREUNDII; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; ESCHERICHIA COLI; GENE EXPRESSION; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; PIPERAZINES; PYRAZOLES;

EID: 84928535085     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.02552-14     Document Type: Article

References (50)

1. Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, Friedland I, Knirsch C, Sanhai WR, Tomayko J, Lancaster C, Jackson J. 2013. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 13:269-275. http://dx.doi.org/10.1016/S1473-3099(12)70293-1.
2. Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079-1081. http://dx.doi.org/10.1086/533452.
3. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Jr. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164. http://dx.doi.org/10.1086/524891.
4. Bugg TD, Braddick D, Dowson CG, Roper DI. 2011. Bacterial cell wall assembly: still an attractive antibacterial target. Trends Biotechnol 29:167-173. http://dx.doi.org/10.1016/j.tibtech.2010.12.006.
5. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29-40. http://dx.doi.org/10.1038/nrd2201.
6. Silver LL. 2011. Challenges of antibacterial discovery. Clin Microbiol Rev 24:71-109. http://dx.doi.org/10.1128/CMR.00030-10.
7. Johnson JW, Fisher JF, Mobashery S. 2013. Bacterial cell-wall recycling. Ann N Y Acad Sci 1277:54-75. http://dx.doi.org/10.1111/j.1749-6632.2012.06813.x.
8. Zeng X, Lin J. 2013. Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. Front Microbiol 4:128. http://dx.doi.org/10.3389/fmicb.2013.00128.
9. Zervosen A, Sauvage E, Frere JM, Charlier P, Luxen A. 2012. Development of new drugs for an old target: the penicillin binding proteins. Molecules 17:12478-12505. http://dx.doi.org/10.3390/molecules171112478.
10. DeCenzo M, Kuranda M, Cohen S, Babiak J, Jiang ZD, Su D, Hickey M, Sancheti P, Bradford PA, Youngman P, Projan S, Rothstein DM. 2002. Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria. J Antibiot (Tokyo) 55:288-295. http://dx.doi.org/10.7164/antibiotics.55.288.
11. Sun D, Cohen S, Mani N, Murphy C, Rothstein DM. 2002. A pathwayspecific cell based screening system to detect bacterial cell wall inhibitors. J Antibiot (Tokyo) 55:279-287. http://dx.doi.org/10.7164/antibiotics.55.279.
12. McLeod SM, Fleming PR, MacCormack K, McLaughlin RE, Whiteaker JD, Narita S, Mori M, Tokuda H, Miller AA. 2015. Small-molecule inhibitors of Gram-negative lipoprotein trafficking discovered by phenotypic screening. J Bacteriol 197:1075-1082. http://dx.doi.org/10.1128/JB.02352-14.
13. Babinski KJ, Ribeiro AA, Raetz CR. 2002. The Escherichia coli gene encoding the UDP-2,3-diacylglucosamine pyrophosphatase of lipid A biosynthesis. J Biol Chem 277:25937-25946. http://dx.doi.org/10.1074/jbc. M204067200.
14. Okuda S, Tokuda H. 2011. Lipoprotein sorting in bacteria. Annu Rev Microbiol 65:239-259. http://dx.doi.org/10.1146/annurev-micro-090110-102859.
15. Yakushi T, Masuda K, Narita S, Matsuyama S, Tokuda H. 2000. A new ABC transporter mediating the detachment of lipid-modified proteins from membranes. Nat Cell Biol 2:212-218. http://dx.doi.org/10.1038/35008635.
16. Wang RF, Kushner SR. 1991. Construction of versatile low-copynumber vectors for cloning, sequencing and gene expression in Escherichia coli. Gene 100:195-199. http://dx.doi.org/10.1016/0378-1119(91)90366-J.
17. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297.
18. Thomason LC, Costantino N, Court DL. 2007. E. coli genome manipulation by P1 transduction. Curr Protoc Mol Biol Chapter 1:Unit 1.17. http://dx.doi.org/10.1002/0471142727.mb0117s79.
19. Rietsch A, Vallet-Gely I, Dove SL, Mekalanos JJ. 2005. ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 102:8006-8011. http://dx.doi.org/10.1073/pnas.0503005102.
20. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 9th ed. Document M07-A8, vol 29, no. 2. Clinical and Laboratory Standards Institute, Wayne, PA.
21. de Jonge BL, Walkup GK, Lahiri SD, Huynh H, Neckermann G, Utley L, Nash TJ, Brock J, San Martin M, Kutschke A, Johnstone M, Laganas V, Hajec L, Gu RF, Ni H, Chen B, Hutchings K, Holt E, McKinney D, Gao N, Livchak S, Thresher J. 2013. Discovery of inhibitors of 4=- phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy. Antimicrob Agents Chemother 57:6005-6015. http://dx.doi.org/10.1128/AAC.01661-13.
22. Keating TA, Newman JV, Olivier NB, Otterson LG, Andrews B, Boriack-Sjodin PA, Breen JN, Doig P, Dumas J, Gangl E, Green OM, Guler SY, Hentemann MF, Joseph-McCarthy D, Kawatkar S, Kutschke A, Loch JT, McKenzie AR, Pradeepan S, Prasad S, Martinez-Botella G. 2012. In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound. ACS Chem Biol 7:1866-1872. http://dx.doi.org/10.1021/cb300316n.
23. Hameed PS, Manjrekar P, Chinnapattu M, Humnabadkar V, Shanbhag G, Kedari C, Mudugal NV, Ambady A, de Jonge BL, Sadler C, Paul B, Sriram S, Kaur P, Guptha S, Raichurkar A, Fleming P, Eyermann CJ, McKinney DC, Sambandamurthy VK, Panda M, Ravishankar S. 2014. Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coli. ACS Chem Biol 9:2274-2282. http://dx.doi.org/10.1021/cb500360c.
24. Nonejuie P, Burkart M, Pogliano K, Pogliano J. 2013. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proc Natl Acad SciUS A 110:16169-16174. http://dx.doi.org/10.1073/pnas.1311066110.
25. Fan J, de Jonge BL, MacCormack K, Sriram S, McLaughlin RE, Plant H, Preston M, Fleming PR, Albert R, Foulk M, Mills SD. 2014. A novel high-throughput cell-based assay aimed at identifying inhibitors of DNAmetabolism in bacteria. Antimicrob Agents Chemother 58:7264-7272. http://dx.doi.org/10.1128/AAC.03475-14.
26. Matsuyama S, Tajima T, Tokuda H. 1995. A novel periplasmic carrier protein involved in the sorting and transport of Escherichia coli lipoproteins destined for the outer membrane. EMBO J 14:3365-3372.
27. Honore N, Nicolas MH, Cole ST. 1986. Inducible cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli. EMBO J 5:3709-3714.
28. Nikaido H. 1998. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 27(Suppl 1):S32-S41. http://dx.doi.org/10.1086/514920.
29. McClerren AL, Endsley S, Bowman JL, Andersen NH, Guan Z, Rudolph J, Raetz CR. 2005. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin. Biochemistry 44:16574-16583. http://dx.doi.org/10.1021/bi0518186.
30. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. http://dx.doi.org/10.1177/108705719900400206.
31. Shapiro AB, Walkup GK, Keating TA. 2009. Correction for interference by test samples in high-throughput assays. J Biomol Screen 14:1008-1016. http://dx.doi.org/10.1177/1087057109341768.
32. Lister PD. 2007. Carbapenems in the USA: focus on doripenem. Expert Rev Anti Infect Ther 5:793-809. http://dx.doi.org/10.1586/14787210.5.5.793.
33. Babinski KJ, Kanjilal SJ, Raetz CR. 2002. Accumulation of the lipid A precursor UDP-2,3-diacylglucosamine in an Escherichia coli mutant lacking the lpxH gene. J Biol Chem 277:25947-25956. http://dx.doi.org/10.1074/jbc. M204068200.
34. Wang X, Quinn PJ. 2010. Lipopolysaccharide: biosynthetic pathway and structure modification. Prog Lipid Res 49:97-107. http://dx.doi.org/10.1016/j.plipres.2009.06.002.
35. Montgomery JI, Brown MF, Reilly U, Price LM, Abramite JA, Arcari J, Barham R, Che Y, Chen JM, Chung SW, Collantes EM, Desbonnet C, Doroski M, Doty J, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, McAllister L, McElroy E, Menard CA, Mitton-Fry M, Mullins L, Noe MC, O'Donnell J, Oliver R, Penzien J, Plummer M, Shanmugasundaram V, Thoma C, Tomaras AP, Uccello DP, Vaz A, Wishka DG. 2012. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J Med Chem 55:1662-1670. http://dx.doi.org/10.1021/jm2014875.
36. Yasuda M, Iguchi-Yokoyama A, Matsuyama S, Tokuda H, Narita S. 2009. Membrane topology and functional importance of the periplasmic region of ABC transporter LolCDE. Biosci Biotechnol Biochem 73:2310-2316. http://dx.doi.org/10.1271/bbb.90451.
37. Choi DS, Yamada H, Mizuno T, Mizushima S. 1986. Trimeric structure and localization of the major lipoprotein in the cell surface of Escherichia coli. J Biol Chem 261:8953-8957.
38. Inouye M, Shaw J, Shen C. 1972. The assembly of a structural lipoprotein in the envelope of Escherichia coli. J Biol Chem 247:8154-8159.
39. Inukai M, Takeuchi M, Shimizu K, Arai M. 1979. Existence of the bound form of prolipoprotein in Escherichia coli B cells treated with globomycin. J Bacteriol 140:1098-1101.
40. Yakushi T, Tajima T, Matsuyama S, Tokuda H. 1997. Lethality of the covalent linkage between mislocalized major outer membrane lipoprotein and the peptidoglycan of Escherichia coli. J Bacteriol 179:2857-2862.
41. Inukai M, Takeuchi M, Shimizu K, Arai M. 1978. Mechanism of action of globomycin. J Antibiot (Tokyo) 31:1203-1205. http://dx.doi.org/10.7164/antibiotics.31.1203.
42. Xiao Y, Gerth K, Muller R, Wall D. 2012. Myxobacterium-produced antibiotic TA (myxovirescin) inhibits type II signal peptidase. Antimicrob Agents Chemother 56:2014-2021. http://dx.doi.org/10.1128/AAC.06148-11.
43. Zwiebel LJ, Inukai M, Nakamura K, Inouye M. 1981. Preferential selection of deletion mutations of the outer membrane lipoprotein gene of Escherichia coli by globomycin. J Bacteriol 145:654-656.
44. Lupoli TJ, Lebar MD, Markovski M, Bernhardt T, Kahne D, Walker S. 2014. Lipoprotein activators stimulate Escherichia coli penicillin-binding proteins by different mechanisms. J Am Chem Soc 136:52-55. http://dx.doi.org/10.1021/ja410813j.
45. Hale MR, Hill P, Lahiri S, Miller MD, Ross P, Alm R, Gao N, Kutschke A, Johnstone M, Prince B, Thresher J, Yang W. 2013. Exploring the UDP pocket of LpxC through amino acid analogs. Bioorg Med Chem Lett 23:2362-2367. http://dx.doi.org/10.1016/j.bmcl.2013.02.055.
46. Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ. 2010. Challenges of antibacterial discovery revisited. Ann N Y Acad Sci 1213:5-19. http://dx.doi.org/10.1111/j.1749-6632.2010.05828.x.
47. O'Shea R, Moser HE. 2008. Physicochemical properties of antibacterial compounds:implications for drug discovery. J Med Chem 51:2871-2878. http://dx.doi.org/10.1021/jm700967e.
48. Silver LL. 2007. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6:41-55. http://dx.doi.org/10.1038/nrd2202.
49. O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR. 2015. Bacterial resistance to leucyltRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother 59:289-298. http://dx.doi.org/10.1128/AAC.03774-14.
50. Rattan A, Kalia A, Ahmad N. 1998. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis 4:195-209. http://dx.doi.org/10.3201/eid0402.980207.